EPIDEMIOLOGY OF PURULENT-SEPTIC INFECTIONS CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS IN THE REPUBLIC OF MOLDOVA

  • V. PRISACARI “Nicolae Testemițanu” PI SUMPh, Chișinău, Republic of Moldova
  • Diana BUGA “Nicolae Testemițanu” PI SUMPh, Chișinău, Republic of Moldova

Abstract

Staphylococcus infections are a major global concern, caused by the annual growth of methicillin-resistant Staphylococcus strains and the emergence of strains resistant to reserve anti-staphylococcal antibiotics. Aim: The aim of the study was to determine the risk factors, the degree of spread of methicillin-resistant Staphylococcus (MRS) strains in health care facilities in the Republic of Moldova, as well as their resistance to antibacterial drugs. Material and methods: The research of the real incidence, epidemiological peculiarities and the degree of sensitivity/resistance of MRS infections to antibiotics was performed based on the descriptive cross-sectional observational epidemiological study, overall being analyzed 10,055 staphylococcal strains. The risk factors and socio-economic impact were determined based on a retrospective case-control study. The research group included 269 patients with bacteriological investigations positive for methicillin-resistant Staphylococcus (MRS), the control group - 159 patients with bacteriological investigations positive for methicillin-sensitive Staphylococcus (MSS). Results: The share of MRS strains among Staphylococcus strains in the Republic of Moldova is on average 35.97%. A higher level of spread of MRS strains is recorded in maternity hospitals - 61.81%, followed by multi-profile health care facilities - 36.32%, slightly lower in rural health care facilities - 22.36%. The prevalence of MRS strains varied depending on the profile of departments and pathological products. Most often, MRS strains were isolated from patients in the departments of surgery, traumatology, orthopedics, resuscitation and intensive care. A high level of MRS was found in blood cultures - 76.11%, and 96.3% of MRS strains isolated from blood proved to be polyresistant.

Author Biographies

V. PRISACARI, “Nicolae Testemițanu” PI SUMPh, Chișinău, Republic of Moldova

Scientific laboratory Hospital-Acquired Infections

Diana BUGA, “Nicolae Testemițanu” PI SUMPh, Chișinău, Republic of Moldova

Scientific laboratory Hospital-Acquired Infections

References

1. Friedrich AW. Control of hospital acquired infections and antimicrobial resistance in Europe: the way to go. Wien Med Wochenschr 2019; 169(1): 25-30.
2. Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019; 19(1): 56-66.
3. Lakhundi S, Zhang K. Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clin Microbiol Rev 2018; 31(4): e00020- e00018.
4. http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_ WHO.pdf
5. https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf;jsessionid=74EF400FB3D3D49EB4021B9186776741?sequence=1
6. Almaş MA. Situaţia actuală a fenomenului de rezistenţă la antibiotice a tulpinilor de stafilococ. Rezumat Teză de doctorat. Cluj-Napoca, 2011.
7. Prisacari V, Buga D, Berdeu I. Nosocomial infections with methicillin resistant Staphylococcus: epidemiogenic situation at day, solutions. AKADEMOS 2017; 4(47): 72-76.
8. Balan G, Burduniuc O, Siniţîna I, Iasâbaş O, Bunescu I. Frecvenţa izolării tulpinilor de Staphylococcus aureus meticilino-rezistente în Republica Moldova. Buletin of the Academy of Sciences of Moldova. Medical Sciences 2017; 1(53): 22-23.
9. Duckworth G. Controlling methicillin resistant Staphylococcus aureus. BMJ 2003; 327(7425): 1177-1178.
10. Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother 2011; 66(4): iv43-iv48.
11. Fluit AC, Wielders CLC, Verhoef J, et al. Epidemiology and susceptibility of 3051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Mi-crobiol 2001; 39: 3727-3732.
12. Stenhem M, Ortqvist A, Ringberg H, et al. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Sweden 2000-2003, increasing incidence and regional differences. BMC Infect Dis 2006; 6: 30 / doi: 10.1186/1471-2334-6-30.
13. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methi-cillin-susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol 2009; 30(5): 453-460.
14. Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 2005; 11(6): 466-4671.
15. Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 2010; 31(4): 365-373.
16. Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, et al. National Costs Associated with Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Hospitalizations in the United States, 2010-2014. Clin Infect Dis. 2019; 68(1): 22-28.
17. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev 2014; 27(4): 870-926.
18. Latif M, Usman J, Gilani M, Munir T, Mushtaq M, Anjum R. Coagulase negative staphylococci - a fast emerging threat. J Pak Med Assoc 2015; 65(3): 283-286.
19. Buga D, Prisacari V, Berdeu I, et al. Situația epidemiogenă prin infecții cu Staphylococcus meticilin-rezistent în Republica Moldova. Sănătate publică, Economie şi Management în medicină 2019; 4 (82): 294-299.
Published
2021-06-30
Section
PREVENTIVE MEDICINE - LABORATORY